Patient, disease, and transplantation characteristics
Characteristics . | No. (%) . | P . | |
---|---|---|---|
Double UCB Transplantation . | Single UCB Transplantation . | ||
No. of patients | 303 | 106 | |
No. of transplantation teams | 45 | 47 | |
Median recipient age, y (range) | 43 (16-71) | 33 (16-69) | < .0001 |
16-20 | 32 (11) | 27 (25) | |
21-30 | 53 (17) | 20 (19) | |
31-40 | 48 (16) | 21 (20) | |
41-50 | 51 (17) | 15 (14) | |
51-60 | 76 (25) | 14 (13) | |
61-71 | 43 (14) | 9 (8) | |
Recipient CMV serostatus transplantation | .52 | ||
Negative | 93 (31) | 35 (33) | |
Positive | 193 (64) | 68 (64) | |
Not reported | 17 (6) | 3 (3) | |
Disease | .34 | ||
Acute myeloid leukemia | 215 (71) | 70 (66) | |
Acute lymphoblastic leukemia | 88 (29) | 36 (34) | |
Disease status | .006 | ||
First complete remission | 135 (45) | 38 (36) | |
Second complete remission | 100 (33) | 31 (29) | |
Third complete remission | 20 (7) | 5 (5) | |
Relapse | 48 (16) | 32 (30) | |
Donor-recipient HLA match | .07 | ||
6/6 | 13 (4) | 10 (9) | |
5/6 | 80 (26) | 33 (31) | |
4/6 | 210 (69) | 63 (59) | |
Conditioning regimen | < .0001 | ||
Myeloablative | |||
TBI + cyclophosphamide* | 94 (31) | 49 (46) | |
TBI + other agents** | 22 (7) | 10 (9) | |
Busulfan + cyclophosphamide*** | 7 (2) | 8 (8) | |
Busulfan + other agents**** | 16 (5) | 10 (9) | |
Reduced intensity | |||
TBI + cyclophosphamide + fludarabine† | 119 (39) | 20 (19) | |
Busulfan + fludarabine†† | 5 (2) | 2 (2) | |
Melphalan + fludarabine††† | 35 (12) | 5 (5) | |
Cyclophosphamide + fludarabine†††† | 5 (2) | 2 (2) | |
GVHD prophylaxis | < .0001 | ||
Tacrolimus alone or with steroid | 8 (3) | 10 (9) | |
Tacrolimus + methotrexate | 6 (2) | 9 (8) | |
Tacrolimus + mycophenolate mofetil | 85 (28) | 20 (19) | |
Cyclosporine alone or with steroid | 8 (3) | 19 (8) | |
Cyclosporine + methotrexate | 1 (< 1) | 6 (6) | |
Cyclosporine + mycophenolate mofetil | 176 (58) | 40 (38) | |
Mycophenolate mofetil + steroid | 1 (< 1) | ||
Not reported | 18 (6) | 2 (2) | |
TNC cryopreserved, ×107/kg (sum of units) | < .0001 | ||
Median dose (range) | 4.5 (2.6-15) | 3.5 (2.5-8.6) | |
2.5-3.0 | 18 (6) | 26 (28) | |
3.0-4.0 | 77 (25) | 47 (43) | |
> 4.0 | 202 (67) | 33 (30) | |
Not reported | 6 (2) | ||
TNC infused, ×107/kg (sum of units) | < .0001 | ||
Median dose (range) | 3.7 (1.8-15.8) | 2.8 (1.0-7.5) | |
< 2.5 | 28 (9) | 30 (28) | |
2.5-3.0 | 49 (16) | 35 (33) | |
3.0-4.0 | 108 (36) | 21 (20) | |
> 4.0 | 111 (37) | 20 (19) | |
Not reported | 6 (2) | ||
Year of transplantation | < .0001 | ||
2002-2004 | 40 (14) | 32 (30) | |
2005-2009 | 263 (86) | 74 (70) | |
Median follow-up, mo (range) | 23 (3-74) | 17 (3-62) |
Characteristics . | No. (%) . | P . | |
---|---|---|---|
Double UCB Transplantation . | Single UCB Transplantation . | ||
No. of patients | 303 | 106 | |
No. of transplantation teams | 45 | 47 | |
Median recipient age, y (range) | 43 (16-71) | 33 (16-69) | < .0001 |
16-20 | 32 (11) | 27 (25) | |
21-30 | 53 (17) | 20 (19) | |
31-40 | 48 (16) | 21 (20) | |
41-50 | 51 (17) | 15 (14) | |
51-60 | 76 (25) | 14 (13) | |
61-71 | 43 (14) | 9 (8) | |
Recipient CMV serostatus transplantation | .52 | ||
Negative | 93 (31) | 35 (33) | |
Positive | 193 (64) | 68 (64) | |
Not reported | 17 (6) | 3 (3) | |
Disease | .34 | ||
Acute myeloid leukemia | 215 (71) | 70 (66) | |
Acute lymphoblastic leukemia | 88 (29) | 36 (34) | |
Disease status | .006 | ||
First complete remission | 135 (45) | 38 (36) | |
Second complete remission | 100 (33) | 31 (29) | |
Third complete remission | 20 (7) | 5 (5) | |
Relapse | 48 (16) | 32 (30) | |
Donor-recipient HLA match | .07 | ||
6/6 | 13 (4) | 10 (9) | |
5/6 | 80 (26) | 33 (31) | |
4/6 | 210 (69) | 63 (59) | |
Conditioning regimen | < .0001 | ||
Myeloablative | |||
TBI + cyclophosphamide* | 94 (31) | 49 (46) | |
TBI + other agents** | 22 (7) | 10 (9) | |
Busulfan + cyclophosphamide*** | 7 (2) | 8 (8) | |
Busulfan + other agents**** | 16 (5) | 10 (9) | |
Reduced intensity | |||
TBI + cyclophosphamide + fludarabine† | 119 (39) | 20 (19) | |
Busulfan + fludarabine†† | 5 (2) | 2 (2) | |
Melphalan + fludarabine††† | 35 (12) | 5 (5) | |
Cyclophosphamide + fludarabine†††† | 5 (2) | 2 (2) | |
GVHD prophylaxis | < .0001 | ||
Tacrolimus alone or with steroid | 8 (3) | 10 (9) | |
Tacrolimus + methotrexate | 6 (2) | 9 (8) | |
Tacrolimus + mycophenolate mofetil | 85 (28) | 20 (19) | |
Cyclosporine alone or with steroid | 8 (3) | 19 (8) | |
Cyclosporine + methotrexate | 1 (< 1) | 6 (6) | |
Cyclosporine + mycophenolate mofetil | 176 (58) | 40 (38) | |
Mycophenolate mofetil + steroid | 1 (< 1) | ||
Not reported | 18 (6) | 2 (2) | |
TNC cryopreserved, ×107/kg (sum of units) | < .0001 | ||
Median dose (range) | 4.5 (2.6-15) | 3.5 (2.5-8.6) | |
2.5-3.0 | 18 (6) | 26 (28) | |
3.0-4.0 | 77 (25) | 47 (43) | |
> 4.0 | 202 (67) | 33 (30) | |
Not reported | 6 (2) | ||
TNC infused, ×107/kg (sum of units) | < .0001 | ||
Median dose (range) | 3.7 (1.8-15.8) | 2.8 (1.0-7.5) | |
< 2.5 | 28 (9) | 30 (28) | |
2.5-3.0 | 49 (16) | 35 (33) | |
3.0-4.0 | 108 (36) | 21 (20) | |
> 4.0 | 111 (37) | 20 (19) | |
Not reported | 6 (2) | ||
Year of transplantation | < .0001 | ||
2002-2004 | 40 (14) | 32 (30) | |
2005-2009 | 263 (86) | 74 (70) | |
Median follow-up, mo (range) | 23 (3-74) | 17 (3-62) |
TBI indicates total body irradiation; TNC, total nucleated cell dose; and UCB, umbilical cord blood.
N = 4 double UCB recipients and N = 13 single UCB recipients received ATG.
N = 4 double UCB recipients and N = 4 single UCB recipients received ATG.
N = 3 double UCB recipients and N = 6 single UCB recipients received ATG.
N = 9 double UCB recipients and N = 6 single UCB recipients received ATG.
N = 35 double UCB recipients and N = 4 single UCB recipients received ATG; TBI dose = 200 cGy
N = 2 double UCB recipients and N = 1 single UCB recipients received ATG.
N = 30 double UCB recipients and N = 4 single UCB recipients received ATG.
N = 2 double UCB recipients and N = 1 single UCB recipients received ATG.